强迫症中的谷氨酸能增强策略。
Glutamatergic augmentation strategies in obsessive-compulsive disorder.
作者信息
Sheshachala Karthik, Narayanaswamy Janardhanan C
机构信息
Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
出版信息
Indian J Psychiatry. 2019 Jan;61(Suppl 1):S58-S65. doi: 10.4103/psychiatry.IndianJPsychiatry_520_18.
Abstract
Proven treatment strategies for obsessive-compulsive disorder (OCD) include pharmacotherapy with serotonin reuptake inhibitors and cognitive behavior therapy (CBT). A significant proportion of patients (25%-30%) fail to respond to these treatment options, necessitating the need for additional treatment options to improve treatment outcomes and quality of life in patients with OCD. Augmentation strategies using various glutamatergic agents have been explored, with diverse outcomes. The aim of this review is to give an overview of the glutamatergic system in the brain with a focus on glutamatergic abnormalities in OCD and to review the existing evidence for various glutamatergic agents used for augmentation.
摘要
强迫症（OCD）经证实的治疗策略包括使用5-羟色胺再摄取抑制剂进行药物治疗以及认知行为疗法（CBT）。相当一部分患者（25%-30%）对这些治疗方案没有反应，因此需要额外的治疗方案来改善强迫症患者的治疗效果和生活质量。人们已经探索了使用各种谷氨酸能药物的增效策略，结果各不相同。这篇综述的目的是概述大脑中的谷氨酸能系统，重点关注强迫症中的谷氨酸能异常，并综述用于增效的各种谷氨酸能药物的现有证据。
相似文献
1
Glutamatergic augmentation strategies in obsessive-compulsive disorder.强迫症中的谷氨酸能增强策略。
Indian J Psychiatry. 2019 Jan;61(Suppl 1):S58-S65. doi: 10.4103/psychiatry.IndianJPsychiatry_520_18.
2
A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.强迫症一线药物治疗抵抗的循证治疗策略系统评价
Curr Med Chem. 2018;25(41):5647-5661. doi: 10.2174/0929867325666171222163645.
3
Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.认知行为疗法联合体重调整的 d-环丝氨酸与安慰剂治疗儿童强迫症的疗效：一项随机临床试验。
JAMA Psychiatry. 2016 Aug 1;73(8):779-88. doi: 10.1001/jamapsychiatry.2016.1128.
4
Serotonin reuptake inhibitor-cognitive behavioural therapy-second generation antipsychotic combination for severe treatment-resistant obsessive-compulsive disorder. A prospective observational study.五羟色胺再摄取抑制剂-认知行为疗法-第二代抗精神病药联合治疗严重治疗抵抗性强迫症。一项前瞻性观察研究。
Int J Psychiatry Clin Pract. 2022 Nov;26(4):395-400. doi: 10.1080/13651501.2022.2054351. Epub 2022 Mar 24.
5
Obsessive compulsive disorder and the glutamatergic system.强迫症与谷氨酸能系统。
Curr Opin Psychiatry. 2014 Jan;27(1):32-7. doi: 10.1097/YCO.0000000000000017.
6
Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.认知行为疗法联合药物治疗儿童强迫症：儿科强迫症治疗研究 II（POTS II）随机对照试验。
JAMA. 2011 Sep 21;306(11):1224-32. doi: 10.1001/jama.2011.1344.
7
N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.N-乙酰半胱氨酸增强疗法治疗5-羟色胺再摄取抑制剂难治性强迫症
Psychopharmacology (Berl). 2006 Jan;184(2):254-6. doi: 10.1007/s00213-005-0246-6. Epub 2005 Dec 22.
8
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.一项系统评价：抗精神病药物增效治疗难治性强迫症
Mol Psychiatry. 2006 Jul;11(7):622-32. doi: 10.1038/sj.mp.4001823. Epub 2006 Apr 4.
9
Mindfulness-based cognitive therapy as an augmentation treatment for obsessive-compulsive disorder.正念认知疗法作为强迫症的增效治疗方法。
Clin Psychol Psychother. 2017 Sep;24(5):1109-1120. doi: 10.1002/cpp.2076. Epub 2017 Feb 13.
10
Assessment and management of treatment-refractory obsessive-compulsive disorder in children.儿童难治性强迫症的评估与管理
J Am Acad Child Adolesc Psychiatry. 2015 Apr;54(4):251-62. doi: 10.1016/j.jaac.2015.01.011. Epub 2015 Jan 30.
引用本文的文献
1
Memantine augmentation of escitalopram in treatment of executive function among patients with obsessive-compulsive disorder (OCD): a double-blind placebo-controlled randomized clinical trial.美金刚增效艾司西酞普兰治疗强迫症患者执行功能的双盲安慰剂对照随机临床试验。
BMC Psychiatry. 2025 Jun 2;25(1):561. doi: 10.1186/s12888-025-06856-7.
2
Psilocybin in pharmacotherapy of obsessive-compulsive disorder.迷幻蘑菇在强迫症药物治疗中的应用。
Pharmacol Rep. 2024 Oct;76(5):911-925. doi: 10.1007/s43440-024-00633-1. Epub 2024 Aug 1.
3
Clinical Effectiveness of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists in Adult Obsessive-Compulsive Disorder (OCD) Treatment: A Systematic Review.N-甲基-D-天冬氨酸（NMDA）受体拮抗剂在成人强迫症（OCD）治疗中的临床疗效：一项系统评价。
Cureus. 2023 Apr 19;15(4):e37833. doi: 10.7759/cureus.37833. eCollection 2023 Apr.
4
Epigenetic modifications and obsessive-compulsive disorder: what do we know?表观遗传学修饰与强迫症：我们了解多少？
Brain Struct Funct. 2023 Jun;228(5):1295-1305. doi: 10.1007/s00429-023-02649-4. Epub 2023 May 19.
5
Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis.谷氨酸能药物作为成人中重度强迫症的辅助治疗：系统评价和荟萃分析。
BMC Pharmacol Toxicol. 2021 Nov 4;22(1):69. doi: 10.1186/s40360-021-00534-6.
6
Brain areas involved with obsessive-compulsive disorder present different DNA methylation modulation.与强迫症相关的大脑区域表现出不同的 DNA 甲基化调节。
BMC Genom Data. 2021 Oct 30;22(1):45. doi: 10.1186/s12863-021-00993-0.
7
Lower Ventromedial Prefrontal Cortex Glutamate Levels in Patients With Obsessive-Compulsive Disorder.强迫症患者腹内侧前额叶皮质下部的谷氨酸水平
Front Psychiatry. 2021 Jun 8;12:668304. doi: 10.3389/fpsyt.2021.668304. eCollection 2021.
8
Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder.难治性强迫症的药物治疗
J Clin Psychiatry. 2020 Sep 8;81(5):19ac13182. doi: 10.4088/JCP.19ac13182.
9
Investigating the Role of Glutamate in Obsessive-Compulsive Disorder: Current Perspectives.探究谷氨酸在强迫症中的作用：当前观点
Neuropsychiatr Dis Treat. 2020 Apr 17;16:1003-1013. doi: 10.2147/NDT.S211703. eCollection 2020.
10
An MRI Study of the Metabolic and Structural Abnormalities in Obsessive-Compulsive Disorder.强迫症患者代谢与结构异常的磁共振成像研究
Front Hum Neurosci. 2019 Jun 26;13:186. doi: 10.3389/fnhum.2019.00186. eCollection 2019.
本文引用的文献
1
Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications.谷氨酸能系统在强迫症中的作用及其可能的治疗意义。
Pharmacopsychiatry. 2018 Nov;51(6):229-242. doi: 10.1055/s-0043-118665. Epub 2017 Sep 26.
2
Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis.利用荟萃分析揭示强迫症的复杂遗传结构。
Mol Psychiatry. 2018 May;23(5):1181-1188. doi: 10.1038/mp.2017.154. Epub 2017 Aug 1.
3
Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.随机、双盲、安慰剂对照试验：N-乙酰半胱氨酸增强治疗抵抗性强迫症。
J Clin Psychiatry. 2017 Jul;78(7):e766-e773. doi: 10.4088/JCP.16m11101.
4
D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: A meta-analysis.D-环丝氨酸增强焦虑症和强迫症行为疗法的Meta分析。
PLoS One. 2017 Mar 10;12(3):e0173660. doi: 10.1371/journal.pone.0173660. eCollection 2017.
5
Clinical practice guidelines for Obsessive-Compulsive Disorder.强迫症临床实践指南。
Indian J Psychiatry. 2017 Jan;59(Suppl 1):S74-S90. doi: 10.4103/0019-5545.196976.
6
7
Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.认知行为疗法联合体重调整的 d-环丝氨酸与安慰剂治疗儿童强迫症的疗效：一项随机临床试验。
JAMA Psychiatry. 2016 Aug 1;73(8):779-88. doi: 10.1001/jamapsychiatry.2016.1128.
8
Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study.利鲁唑联合氟伏沙明治疗中重度强迫症的随机双盲安慰剂对照研究。
Psychiatry Clin Neurosci. 2016 Aug;70(8):332-41. doi: 10.1111/pcn.12394. Epub 2016 May 26.
9
Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial.基于暴露的认知行为疗法能否延长静脉注射氯胺酮治疗强迫症的效果？一项开放标签试验。
J Clin Psychiatry. 2016 Mar;77(3):408-9. doi: 10.4088/JCP.15l10138.
10
N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.N-乙酰半胱氨酸强化疗法治疗中重度强迫症：随机、双盲、安慰剂对照试验
J Clin Pharm Ther. 2016 Apr;41(2):214-9. doi: 10.1111/jcpt.12370. Epub 2016 Mar 2.
Zotero 插件